Galectin Therapeutics's top three insider shareholders as of March 23, 2026 are Richard E Uihlein (Director, 10.33Mn shares), James C Czirr (TenPercentOwner, 5.92Mn shares), Fund, L.P. 10X (TenPercentOwner, 5.67Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Richard E Uihlein | 10,332,676 | 0 | 21 Jan, 2026 | |
| James C Czirr | 0 | 5,922,207 | 25 Apr, 2024 | |
| Fund, L.P. 10X | 5,670,138 | 0 | 08 Dec, 2025 | |
| Joel Lewis | President And Ceo | 776,260 | 0 | 13 Jan, 2026 |
| Kevin D Freeman | 0 | 80,000 | 16 Oct, 2024 | |
| Kary Eldred | 65,682 | 0 | 09 Feb, 2026 | |
| Kevin D Freeman | 55,269 | 0 | 23 Dec, 2025 | |
| Richard A. Jr. Zordani | 42,083 | 0 | 26 Dec, 2024 | |
| Jack W Callicutt | Chief Financial Officer | 7,614 | 0 | 06 Jan, 2026 |
| Harold H. Shlevin | 6,500 | 0 | 19 Dec, 2025 | |
| Joel Lewis | President And Ceo | 0 | 2,000 | 25 Apr, 2024 |
| Richard A. Jr. Zordani | 0 | 2,000 | 26 Aug, 2024 | |
| Elissa J. Schwartz | 1,000 | 0 | 24 Jan, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 12 Mar, 2026 | Henry Brem | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 06 Feb, 2026 | Kary Eldred | Common Stock | A | 300 | $2.70 | 65,682 | D | P |
| 16 Jan, 2026 | Joel Lewis | Stock option (right to buy) | A | 91,000 | $0.00 | 91,000 | D | A |
| 16 Jan, 2026 | Richard E Uihlein | Common Stock | A | 13,158 | $3.04 | 10,332,676 | D | A |
| 16 Jan, 2026 | Richard A. Jr. Zordani | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 16 Jan, 2026 | Elissa J. Schwartz | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 16 Jan, 2026 | Kary Eldred | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 16 Jan, 2026 | Jack W Callicutt | Stock option (right to buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 16 Jan, 2026 | Gilbert F Amelio | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 16 Jan, 2026 | Khurram Jamil | Stock option (right to buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 16 Jan, 2026 | Gilbert S Omenn | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 16 Jan, 2026 | Harold H. Shlevin | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 16 Jan, 2026 | Joel Lewis | Stock option (right to buy) | A | 84,000 | $0.00 | 65,000 | D | A |
| 16 Jan, 2026 | Kevin D Freeman | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 16 Jan, 2026 | Benjamin Sr Carson | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 16 Jan, 2026 | Khurram Jamil | Restricted Stock Unit | A | 100,000 | $0.00 | 100,000 | D | A |
| 16 Jan, 2026 | Jack W Callicutt | Restricted Stock Unit | A | 100,000 | $0.00 | 100,000 | D | A |
| 16 Jan, 2026 | Joel Lewis | Restricted Stock Unit | A | 120,000 | $0.00 | 100,000 | D | A |
| 16 Jan, 2026 | Richard E Uihlein | Stock option (right to buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 05 Jan, 2026 | Joel Lewis | Common Stock | D | 56,332 | $3.88 | 776,260 | D |